ArticleGenes & cancer2011
Lymphangiogenesis and cancer.
Article in Genes & cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed.
- Development and validation of a preoperative CT-based radiomic nomogram to predict pathology invasiveness in patients with a solitary pulmonary nodule: a machine learning approach, multicenter, diagnostic study.European radiology · 2022Trial
- Combining lipiodol-based indirect radiography and intraoperative methylene blue for sentinel lymph node mapping in canine cutaneous mast cell tumors.Veterinary research communications · 2026Article
- 3D Engineered Biomimetic Platform for Characterization of Collective Invasion, Tumor Emboli Formation, and Lymphatic Dissemination.IEEE open journal of engineering in medicine and biology · 2026Article
- Tertiary Lymphoid Structures in Tuberculosis: Persistence, Protection, and Pathology.Immunological reviews · 2025Review
- MRI radiomics for diagnosing small BI-RADS 4 breast lesions: an interpretable model.Quantitative imaging in medicine and surgery · 2025Article
- DCE-MRI radiomics of primary breast lesions combined with ipsilateral axillary lymph nodes for predicting efficacy of NAT.BMC cancer · 2025Article
- Interpretable machine learning model for predicting clinically significant prostate cancer: integrating intratumoral and peritumoral radiomics with clinical and metabolic features.BMC medical imaging · 2024Article
- Visualizing the Tumor Microenvironment: Molecular Imaging Probes Target Extracellular Matrix, Vascular Networks, and Immunosuppressive Cells.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Nomogram using intratumoral and peritumoral radiomics for the preoperative prediction of visceral pleural invasion in clinical stage IA lung adenocarcinoma.Journal of cardiothoracic surgery · 2024Article
- VE-cadherin junction dynamics in initial lymphatic vessels promotes lymph node metastasis.Life science alliance · 2024Article
- Development and validation of ultrasound-based radiomics model to predict germline BRCA mutations in patients with breast cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Current and Developing Lymphatic Imaging Approaches for Elucidation of Functional Mechanisms and Disease Progression.Molecular imaging and biology · 2024Review
- Molecular Profiling of Lymphatic Endothelial Cell Activation In Vitro.International journal of molecular sciences · 2023Article
- The Lymphatic Endothelial Cell Secretome Inhibits Osteoblast Differentiation and Bone Formation.Cells · 2023Article
- Melanoma-derived mediators can foster the premetastatic niche: crossroad to lymphatic metastasis.Trends in immunology · 2023Review
- Article
- The Carotenoid Diatoxanthin Modulates Inflammatory and Angiogenesis Pathways In Vitro in Prostate Cancer Cells.Antioxidants (Basel, Switzerland) · 2023Article
- Development of an interpretable machine learning model for Ki-67 prediction in breast cancer using intratumoral and peritumoral ultrasound radiomics features.Frontiers in oncology · 2023Article
- Advancements in Cancer Immunotherapies.Vaccines · 2022Review
- Visible Lymph Affluents in the D3 Volume: An MDCTA Pictorial Essay.Diagnostics (Basel, Switzerland) · 2022Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Historically, lymphatic vessels were considered passive participants in tumor metastasis by simply providing channels for tumor cells to transit to draining lymph nodes. The discovery of several key lymphatic-specific molecular markers and an increased availability of in vitro and in vivo experimental systems to study lymphatic biology have however highlighted a much more complex, active role for the lymphatic vasculature in metastatic tumor spread. This review will briefly describe the lymphatic system and lymphangiogenesis and then focus on the role of the lymphatic system in cancer metastasis. The progression of our understanding from the lymphatic system as a somewhat passive conduit for metastasis to an active participant in metastatic tumor dissemination, regulated by a complex array of lymphangiogenic factors, chemokines, and immune cell subsets, will be described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.